Evotec and Boehringer Ingelheim Extend and Broaden Research Collaboration

2009-11-09 10:28:02 -

London, November , 09, 2009

Corporate news announcement processed and transmitted by Hugin AS.

The issuer is solely responsible for the content of this 

announcement. 

----------------------------------------------------------------------

--------------    









- Strategic research collaboration continues for another 4 years at a

value of EUR 15 million plus milestones and royalties -



Hamburg, Germany - 9 November 2009: Evotec AG (Frankfurt Stock

Exchange: EVT; TecDAX, NASDAQ: EVTC) today announced that it has

extended the research collaboration with Boehringer Ingelheim for a

further 4 years. The collaboration was initiated in August 2004 and

has been extended on two previous occasions. At the same time, based

on the success to date in the areas of CNS, inflammation,

cardiometabolic and respiratory diseases the scope of the

collaboration has been expanded to also include oncology targets.

Over the term of the extension Evotec will receive research funding

of around EUR 15 million plus success milestones and royalties.



Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented:

"We are extremely pleased and proud that Boehringer Ingelheim

continues to see the value that we bring to their research, by

committing to one of the largest and most innovative integrated

research projects in the industry. This extension speaks volumes for

the excellent scientific results achieved."



Dr Wolfgang Rettig, Corporate Senior Vice President Research of

Boehringer Ingelheim, commented: "Evotec has continually demonstrated

exceptional scientific expertise in support of our research. We are

very pleased to be able to continue our collaboration with Evotec and

expand it into new areas of research and have no doubt that they will

continue to assist us in achieving our drug discovery goals."



About the Collaboration

In 2004, Evotec and Boehringer Ingelheim entered into a multiyear

drug discovery collaboration to jointly identify and develop

preclinical development candidates for the treatment of various

diseases. Under the terms of the agreement, Boehringer Ingelheim has

full ownership and global responsibility for clinical development,

manufacturing and commercialisation of the compounds identified. In

return, Evotec receives ongoing research payments and preclinical

milestones. Furthermore, the contract provides substantial long-term

upside for Evotec through potential payments for successful milestone

achievements during clinical development and royalties when new drugs

reach the market.



Contact: Dr Werner Lanthaler, Chief Executive Officer,

Evotec AG, Tel.: +49.(0)40.56081-242,  werner.lanthaler@evotec.com



Forward-Looking Statements

Information set forth in this press release contains forward-looking

statements, which involve a number of risks and uncertainties. Such

forward-looking statements include, but are not limited to,

statements about our expectations and assumptions concerning

regulatory, clinical and business strategies, the progress of our

clinical development programs and timing of the results of our

clinical trials, strategic collaborations and management's plans,

objectives and strategies. These statements are neither promises nor

guarantees, but are subject to a variety of risks and uncertainties,

many of which are beyond our control, and which could cause actual

results to differ materially from those contemplated in these

forward-looking statements. In particular, the risks and

uncertainties include, among other things: risks that the Company may

be unable to reduce its cash burn through recent restructuring and

cost containment measures and may not recognize the results of such

measures within the expected timeframe; risks that product candidates

may fail in the clinic or may not be successfully marketed or

manufactured; the risk that we will not achieve the anticipated

benefits of our collaborations, partnerships and acquisitions in the

timeframes expected, or at all; risks relating to our ability to

advance the development of product candidates currently in the

pipeline or in clinical trials; our inability to further identify,

develop and achieve commercial success for new products and

technologies; the risk that competing products may be more

successful; our inability to interest potential partners in our

technologies and products; our inability to achieve commercial

success for our products and technologies; our inability to protect

our intellectual property and the cost of enforcing or defending our

intellectual property rights; our failure to comply with regulations

relating to our products and product candidates, including FDA

requirements; the risk that the FDA may interpret the results of our

studies differently than we have; the risk that clinical trials may

not result in marketable products; the risk that we may be unable to

successfully secure regulatory approval of and market our drug

candidates; and risks of new, changing and competitive technologies

and regulations in the U.S. and internationally.

The list of risks above is not exhaustive. Our most recent Annual

Report on Form 20-F, filed with the Securities and Exchange

Commission, and other documents filed with, or furnished to the

Securities and Exchange Commission, contain additional factors that

could impact our businesses and financial performance. We expressly

disclaim any obligation or undertaking to release publicly any

updates or revisions to any such statements to reflect any change in

our expectations or any change in events, conditions or circumstances

on which any such statement is based.




 hugin.info/131215/R/1353562/327876.pdf





 

--- End of Message ---



Evotec AG

Schnackenburgallee 114 Hamburg Germany



WKN: 566480; ISIN: 

DE0005664809 ; Index: Prime All Share, CDAX, HDAX, MIDCAP, TECH All 

Share;

Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in 

Börse Berlin, 

Freiverkehr in Bayerische Börse München, Freiverkehr in Börse 

Düsseldorf, 

Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische 

Wertpapierbörse zu Hamburg, 

Freiverkehr in Niedersächsische Börse zu Hannover, Regulierter Markt 

in Frankfurter Wertpapierbörse;